PMID- 31825468
OWN - NLM
STAT- MEDLINE
DCOM- 20201019
LR  - 20201019
IS  - 1755-3245 (Electronic)
IS  - 0008-6363 (Linking)
VI  - 116
IP  - 5
DP  - 2020 Apr 1
TI  - Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from 
      mechanistic studies in humans to clinical outcomes.
PG  - 916-930
LID - 10.1093/cvr/cvz323 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is currently one of the most prevalent diseases, 
      with as many as 415 million patients worldwide. T2DM is characterized by elevated 
      blood glucose levels and is often accompanied by several comorbidities, such as 
      cardiovascular disease. Treatment of T2DM is focused on reducing glucose levels 
      by either lifestyle changes or medical treatment. One treatment option for T2DM 
      is based on the gut-derived hormone glucagon-like peptide 1 (GLP-1). GLP-1 
      reduces blood glucose levels by stimulating insulin secretion, however, it is 
      rapidly degraded, and thereby losing its glycaemic effect. GLP-1 receptor 
      agonists (GLP-1RAs) are immune to degradation, prolonging the glycaemic effect. 
      Lately, GLP-1RAs have spiked the interest of researchers and clinicians due to 
      their beneficial effects on cardiovascular disease. Preclinical and clinical data 
      have demonstrated that GLP-1 receptors are abundantly present in the heart and 
      that stimulation of these receptors by GLP-1 has several effects. In this review, 
      we will discuss the effects of GLP-1RA on heart rate, blood pressure, 
      microvascular function, lipids, and inflammation, as measured in human 
      mechanistic studies, and suggest how these effects may translate into the 
      improved cardiovascular outcomes as demonstrated in several trials.
CI  - Published on behalf of the European Society of Cardiology. All rights reserved. (c) 
      The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.
FAU - Heuvelman, Valerie D
AU  - Heuvelman VD
AD  - Diabetes Center, Department of Internal Medicine, Amsterdam University Medical 
      Center, Location VUmc, De Boelelaan 1117, Room ZH 4A72, 1081 HV Amsterdam, The 
      Netherlands.
FAU - Van Raalte, Daniel H
AU  - Van Raalte DH
AD  - Diabetes Center, Department of Internal Medicine, Amsterdam University Medical 
      Center, Location VUmc, De Boelelaan 1117, Room ZH 4A72, 1081 HV Amsterdam, The 
      Netherlands.
FAU - Smits, Mark M
AU  - Smits MM
AD  - Diabetes Center, Department of Internal Medicine, Amsterdam University Medical 
      Center, Location VUmc, De Boelelaan 1117, Room ZH 4A72, 1081 HV Amsterdam, The 
      Netherlands.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Cardiovasc Res
JT  - Cardiovascular research
JID - 0077427
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (GLP1R protein, human)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Incretins)
SB  - IM
MH  - Animals
MH  - Biomarkers/blood
MH  - Blood Glucose/*drug effects/metabolism
MH  - Cardiovascular Diseases/epidemiology/metabolism/physiopathology/*prevention & 
      control
MH  - Cardiovascular System/*drug effects/metabolism/physiopathology
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy/epidemiology
MH  - Glucagon-Like Peptide-1 Receptor/*agonists/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects/*therapeutic use
MH  - Incretins/adverse effects/*therapeutic use
MH  - Risk Factors
MH  - Signal Transduction
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Blood pressure
OT  - Cardiovascular
OT  - Diabetes
OT  - Dyslipidemia
OT  - GLP-1 receptor agonist
OT  - Outcome
EDAT- 2019/12/12 06:00
MHDA- 2020/10/21 06:00
CRDT- 2019/12/12 06:00
PHST- 2019/04/25 00:00 [received]
PHST- 2019/09/11 00:00 [revised]
PHST- 2019/12/09 00:00 [accepted]
PHST- 2019/12/12 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2019/12/12 06:00 [entrez]
AID - 5673388 [pii]
AID - 10.1093/cvr/cvz323 [doi]
PST - ppublish
SO  - Cardiovasc Res. 2020 Apr 1;116(5):916-930. doi: 10.1093/cvr/cvz323.